earnings
confidence high
sentiment negative
materiality 0.75
Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance
GILEAD SCIENCES, INC.
2025-Q1 EPS reported
$1.04
revenue$6,667,000,000
- Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.
- GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).
- Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.
- Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.
- Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1.